Background
Acute pulmonary exacerbation (APE) in cystic fibrosis patients is frequent and associated with a decline in pulmonary function, quality of life and survival. Tobramycin is often used in regimens requiring activity against Pseudomonas aeruginosa , however, an important number of centers do not use official dosing recommendation. The current dosing strategy may be suboptimal.